MediPharm Labs Corp. (TSX:LABS)
Canada
· Delayed Price · Currency is CAD 0.0900
+0.0150 (20.00%)
Apr 28, 2026, 3:56 PM EST
MediPharm Labs Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 45.12 | 41.96 | 33.06 | 22.12 | 21.71 | Upgrade
|
| Revenue Growth (YoY) | 7.54% | 26.92% | 49.49% | 1.87% | -39.71% | Upgrade
|
| Cost of Revenue | 31.26 | 29.27 | 24.96 | 24.19 | 35.13 | Upgrade
|
| Gross Profit | 13.86 | 12.69 | 8.1 | -2.07 | -13.42 | Upgrade
|
| Selling, General & Admin | 20.73 | 21.96 | 21.07 | 24.4 | 30.87 | Upgrade
|
| Research & Development | 0.22 | 0.32 | 0.29 | 1.12 | 1.51 | Upgrade
|
| Other Operating Expenses | 0.17 | 0.26 | 0.07 | 0.17 | -0.07 | Upgrade
|
| Operating Expenses | 21.08 | 22.62 | 21.42 | 25.7 | 32.3 | Upgrade
|
| Operating Income | -7.22 | -9.94 | -13.32 | -27.77 | -45.72 | Upgrade
|
| Interest Expense | -0.06 | -0.58 | -0.37 | -0.03 | -10.51 | Upgrade
|
| Interest & Investment Income | 0.23 | 0.69 | 0.84 | 0.48 | 0.23 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.04 | 0.05 | -0.46 | -0.74 | -1.67 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | 0 | 4.51 | Upgrade
|
| EBT Excluding Unusual Items | -7.09 | -9.78 | -13.3 | -28.06 | -53.16 | Upgrade
|
| Merger & Restructuring Charges | -1.19 | -0.96 | -4.42 | -1.04 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.12 | 0.3 | -0.08 | -0.91 | - | Upgrade
|
| Asset Writedown | -0.12 | -0.26 | -0.22 | - | -6.29 | Upgrade
|
| Other Unusual Items | - | - | 4.67 | 0.02 | 4.76 | Upgrade
|
| Pretax Income | -8.27 | -10.69 | -13.36 | -29.99 | -54.69 | Upgrade
|
| Income Tax Expense | - | - | -0.28 | -0.01 | 0.11 | Upgrade
|
| Earnings From Continuing Operations | -8.27 | -10.69 | -13.08 | -29.98 | -54.8 | Upgrade
|
| Net Income | -8.27 | -10.69 | -13.08 | -29.98 | -54.8 | Upgrade
|
| Net Income to Common | -8.27 | -10.69 | -13.08 | -29.98 | -54.8 | Upgrade
|
| Shares Outstanding (Basic) | 418 | 408 | 363 | 277 | 250 | Upgrade
|
| Shares Outstanding (Diluted) | 418 | 408 | 363 | 277 | 250 | Upgrade
|
| Shares Change (YoY) | 2.53% | 12.29% | 31.23% | 10.79% | 80.37% | Upgrade
|
| EPS (Basic) | -0.02 | -0.03 | -0.04 | -0.11 | -0.22 | Upgrade
|
| EPS (Diluted) | -0.02 | -0.03 | -0.04 | -0.11 | -0.22 | Upgrade
|
| Free Cash Flow | -5.6 | -5.02 | -12.81 | -16.93 | -14 | Upgrade
|
| Free Cash Flow Per Share | -0.01 | -0.01 | -0.04 | -0.06 | -0.06 | Upgrade
|
| Gross Margin | 30.71% | 30.24% | 24.50% | -9.38% | -61.81% | Upgrade
|
| Operating Margin | -16.00% | -23.68% | -40.30% | -125.56% | -210.59% | Upgrade
|
| Profit Margin | -18.32% | -25.49% | -39.57% | -135.56% | -252.41% | Upgrade
|
| Free Cash Flow Margin | -12.42% | -11.95% | -38.75% | -76.56% | -64.46% | Upgrade
|
| EBITDA | -5.59 | -7.4 | -10.92 | -24.99 | -40.42 | Upgrade
|
| EBITDA Margin | -12.40% | -17.64% | -33.02% | -112.99% | -186.17% | Upgrade
|
| D&A For EBITDA | 1.63 | 2.54 | 2.41 | 2.78 | 5.3 | Upgrade
|
| EBIT | -7.22 | -9.94 | -13.32 | -27.77 | -45.72 | Upgrade
|
| EBIT Margin | -16.00% | -23.68% | -40.30% | -125.56% | -210.59% | Upgrade
|
| Revenue as Reported | 45.12 | 41.96 | 33.06 | 22.12 | - | Upgrade
|
| Advertising Expenses | 0.8 | 0.87 | 1.27 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.